

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT

This is a voluntary announcement made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”). The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on November 29, 2023, the Company entered into a non-legally binding strategic partnership agreement (the “**Strategic Partnership Agreement**”) with Yangtze River Pharmaceutical Group (揚子江藥業集團有限公司) (“**Yangtze River**”).

Established in 1971, Yangtze River is a sizeable pharmaceutical group that operates across regions. It integrates industry, academia and research, and synergizes science, industry and trade. It is also one of the first batch of “Innovative Enterprises” listed by the Ministry of Science and Technology of the People’s Republic of China. Its main products include both western medicines and traditional Chinese medicines, covering 15 therapeutic areas and 565 specifications, of which 102 have been exported to 38 countries and regions. Yangtze River (Hong Kong) Limited (“**Yangtze HK**”), a close associate of Yangtze River, is a cornerstone investor of the Company in its global offering and holds less than 0.5% of the total issued shares of the Company as at the date of this announcement.

The strategic partnership between the Company and Yangtze River mainly centers around digital marketing services for certain chronic disease areas. The parties will explore and deepen their business scopes and business depth in the field of chronic condition management. Pursuant to the Strategic Partnership Agreement, the Company and Yangtze River hope to establish long-term strategic cooperation in the area of pharmaceutical digital marketing. Based on digital SaaS, the parties hope to foster new business forms, to promote the industry to be more intelligent, higher-end and greener, and to increase the accessibility of medicines for patients with chronic conditions.

The Board considers that the Strategic Partnership Agreement provides a valuable opportunity to the parties to leverage their respective resources and expertise and create mutual benefits and synergy to each other. Therefore, the Board is of the view that entering into the Strategic Partnership Agreement is in the interest of the Company and its shareholders as a whole.

To the best of the knowledge, information and belief of the Board having made all reasonable enquiries, Yangtze River and Yangtze HK are each a third party independent of the connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company. Further announcement(s) in relation to possible cooperation(s) will be made by the Company as and when appropriate in compliance with the Listing Rules. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, November 30, 2023

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*